Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IART
stocks logo

IART

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
395.06M
-5.53%
0.431
-31.57%
418.83M
+9.98%
0.577
+40.73%
470.29M
+6.25%
0.815
-16%
Estimates Revision
The market is revising Downward the revenue expectations for Integra LifeSciences Holdings Corporation (IART) for FY2025, with the revenue forecasts being adjusted by -0.74% over the past three months. During the same period, the stock price has changed by -26.73%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.74%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-8.77%
In Past 3 Month
Stock Price
Go Down
down Image
-26.73%
In Past 3 Month
7 Analyst Rating
up Image0
Wall Street analysts forecast IART stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IART is 15.00 USD with a low forecast of 10.00 USD and a high forecast of 25.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
3 Hold
3 Sell
Moderate Sell
up Image0
Current: 11.130
sliders
Low
10.00
Averages
15.00
High
25.00
up Image0
Current: 11.130
sliders
Low
10.00
Averages
15.00
High
25.00
Citizens JMP
Outperform
downgrade
$35 -> $25
2025-05-09
Reason
Citizens JMP
Price Target
$35 -> $25
2025-05-09
downgrade
Outperform
Reason
Citizens JMP lowered the firm's price target on Integra LifeSciences to $25 from $35 and keeps an Outperform rating on the shares. Integra's Q1 sales and earnings results were within guidance ranges, but expectations for Q2 were a bit below, the analyst tells investors in a research note. The firm views Monday's 20% selloff on this news as overdone.
Truist Securities
Richard Newitter
Hold
Maintains
$26 → $19
2025-04-11
Reason
Truist Securities
Richard Newitter
Price Target
$26 → $19
2025-04-11
Maintains
Hold
Reason
Truist lowered the firm's price target on Integra LifeSciences to $19 from $26 and keeps a Hold rating on the shares as part of a broad research note previewing Q1 results in Medical Technology. The group's revenue and earnings are less at risk than it could be for a number of other sub-sectors, which will likely keep investors relatively interested in the space even with some tariff choppiness in the backdrop, though the firm is also bracing for cautious 2025 outlooks as companies and models will likely begin to dial-in some macro uncertainty, the analyst tells investors in a research note.
Argus Research
David Toung
Hold
to
Strong Buy
Upgrades
n/a
2025-03-31
Reason
Argus Research
David Toung
Price Target
n/a
2025-03-31
Upgrades
Hold
to
Strong Buy
Reason
Argus upgraded Integra LifeSciences to Buy from Hold.
Citizens Capital Markets
David Turkaly
Buy
Reiterates
$35
2025-02-26
Reason
Citizens Capital Markets
David Turkaly
Price Target
$35
2025-02-26
Reiterates
Buy
Reason
Citigroup
Joanne Wuensch
Strong Sell
Maintains
$16 → $22
2024-11-05
Reason
Citigroup
Joanne Wuensch
Price Target
$16 → $22
2024-11-05
Maintains
Strong Sell
Reason
Truist Securities
Richard Newitter
Hold
Maintains
$26 → $21
2024-10-14
Reason
Truist Securities
Richard Newitter
Price Target
$26 → $21
2024-10-14
Maintains
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Integra Lifesciences Holdings Corp (IART.O) is 5.11, compared to its 5-year average forward P/E of 15.42. For a more detailed relative valuation and DCF analysis to assess Integra Lifesciences Holdings Corp 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
15.42
Current PE
5.11
Overvalued PE
20.64
Undervalued PE
10.19

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average EV/EBITDA
13.66
Current EV/EBITDA
8.17
Overvalued EV/EBITDA
16.67
Undervalued EV/EBITDA
10.65

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
2.45
Current PS
0.56
Overvalued PS
3.48
Undervalued PS
1.43

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders areSelling! The selling amount has increased 449.26% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 449.26% over the last month.
Sold
Bought

IART News & Events

Events Timeline

(ET)
2025-07-02
16:14:18
Integra LifeSciences enrolls first patient in Acclarent AERA Pediatric Registry
select
2025-05-05 (ET)
2025-05-05
06:35:39
Integra LifeSciences lowers adj 2025 EPS view to $2.19-$2.29 from $2.41-$2.51
select
2025-05-05
06:32:45
Integra LifeSciences sees Q2 adjusted EPS 40c-45c, consensus 57c
select
Sign Up For More Events
Sign Up For More Events

News

Preview
9.5
07-15Newsfilter
Integra LifeSciences to Host Second Quarter 2025 Financial Results Conference Call on July 31, 2025

  • Earnings Release Announcement: Integra LifeSciences Holdings Corporation will announce its second quarter 2025 financial results on July 31, 2025, with a conference call scheduled for 8:30 a.m. ET that day.

  • Company Overview: Integra LifeSciences focuses on innovative medical technologies aimed at improving patient outcomes in surgical, neurologic, and regenerative care, offering a wide range of high-quality products.

Preview
9.0
07-03Newsfilter
Integra LifeSciences Announces First Patient Enrolled in Acclarent AERA® Pediatric Registry

  • First Patient Enrolled in Pediatric Registry: Integra LifeSciences has announced the enrollment of the first patient in the Acclarent AERA Pediatric Registry, which aims to evaluate the real-world use of the AERA Eustachian Tube Balloon Dilation System in children with obstructive Eustachian tube dysfunction.

  • Registry Goals and Outcomes: The registry will assess safety and efficacy outcomes for up to 300 pediatric patients undergoing Eustachian tube balloon dilation, focusing on failure-free status post-procedure and capturing various clinical data to enhance understanding and treatment of pediatric ENT conditions.

Preview
7.0
06-18Globenewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART

  • Investigation Announcement: Pomerantz LLP is investigating potential securities fraud claims against Integra LifeSciences Holdings Corporation following disappointing financial results and significant stock price decline.

  • Financial Performance Details: Integra reported a loss of -$0.33 per diluted share for Q1 2025, missing earnings guidance and revenue outlook, leading to a 21.19% drop in stock price on May 5, 2025.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Integra Lifesciences Holdings Corp (IART) stock price today?

The current price of IART is 11.13 USD — it has decreased -7.1 % in the last trading day.

arrow icon

What is Integra Lifesciences Holdings Corp (IART)'s business?

Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. It provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, plastics and surgical reconstruction products, and others.

arrow icon

What is the price predicton of IART Stock?

Wall Street analysts forecast IART stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IART is 15.00 USD with a low forecast of 10.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Integra Lifesciences Holdings Corp (IART)'s revenue for the last quarter?

Integra Lifesciences Holdings Corp revenue for the last quarter amounts to 382.65M USD, increased 3.74 % YoY.

arrow icon

What is Integra Lifesciences Holdings Corp (IART)'s earnings per share (EPS) for the last quarter?

Integra Lifesciences Holdings Corp. EPS for the last quarter amounts to -0.33 USD, increased 725.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Integra Lifesciences Holdings Corp (IART)'s fundamentals?

The market is revising Downward the revenue expectations for Integra LifeSciences Holdings Corporation (IART) for FY2025, with the revenue forecasts being adjusted by -0.74% over the past three months. During the same period, the stock price has changed by -26.73%.
arrow icon

How many employees does Integra Lifesciences Holdings Corp (IART). have?

Integra Lifesciences Holdings Corp (IART) has 4396 emplpoyees as of July 19 2025.

arrow icon

What is Integra Lifesciences Holdings Corp (IART) market cap?

Today IART has the market capitalization of 864.94M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free